Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2019

View Archived Issues

GABA Therapeutics and ATAI Life Sciences to develop GRX-917 for the treatment of mood disorders

Senolytics work as advertised

European Commission approves Epidyolex for the treatment of LGS and Dravet syndrome

Ovid announces positive initial data from ongoing ENDYMION extension trial of soticlestat

Phase III study of StrataGraft regenerative tissue meets both primary endpoints

PhoenixMD receives FDA clearance to initiate phase I/Ib study of PMD-026

Positive topline results presented from phase II STAR study of tolperisone

Nanobiotix presents phase I data from phase I/II study of NBTXR-3 in HCC

Phase I study of the oncolytic virus DNX-2401 in diffuse intrinsic pontine glioma

Trabectedin does not improve PFS and OS compared to standard of care in patients with meningioma

CRISPR/Cas9-mediated editing of hepatic G6pc as new model of glycogen storage disease type 1

Discovery of a novel 5-miRNA biomarker panel for early detection of NSCLC

New approach prevents GvHD, unintended consequences

Psoriasis drugs may be repurposed to treat osteosarcoma

Cytokines found to be prognostic in stage IA lung adenocarcinoma

Synthesis and evaluation of a novel radiolabeled peptide targeting GnRH receptor for prostate cancer

Novel mouse model of pancreatic cancer-induced cachexia mimicking human features

Bristol-Myers Squibb patents FPR1 and FPR2 agonists

Novartis patent details HBsAg secretion inhibitors

Inflazome reports new NLRP3 inflammasome inhibitors

Reaction Biology prepares and tests HDAC inhibitors

Pediatric phase III trial of dasiglucagon for severe hypoglycemia meets primary endpoint

Constellation begins phase I/II trial of CPI-0209 in advanced solid tumors

Incyte identifies PI3Kgamma inhibitors

FDA clears Linnaeus' IND for phase I/II trial of LNS-8801 in advanced cancer

FDA accepts Tarsius' IND for TRS-01 for ocular diseases

European Commission approves Vitrakvi for solid tumors with NTRK gene fusion

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...